If you are living with type 2 diabetes, it’s time to talk about your increased risk of cardiovascular events.  

Fortunately, the SURPASS-CVOT clinical research study is currently underway in your area.  We are looking for volunteers to join SURPASS-CVOT, a clinical research trial that will test how effective an investigational study drug is when compared to dulaglutide (an approved diabetes medication) on major adverse cardiovascular events in people with type 2 diabetes mellitus (T2DM), and a history of cardiovascular disease (CVD). 

Any trial-related investigational medications, laboratory tests and assessments that are over and above normal medical care will be provided at no cost to you. Reimbursement may also be available for trial-related expenses (such as travel).

If you would like to know more, please contact us. We will be happy to answer any questions that you may have. We can also schedule an appointment so that you can learn about the study in detail and allow us to check whether you and the study are a good match.

Type of participant we are looking for:

• Diagnosed with type 2 diabetes
• Be at least 40 years of age
• Have established cardiovascular disease (e.g. History of heart attack, stroke, vascular stents, bypass, peripheral artery disease)

Clinicaltrials.gov number
NCT04255433

Who to contact:
Karen Atkinson, Ellen Demmerle
Phone number: 206-768-5338 

BRIDge is a research study to facilitate the understanding of diabetes and immune-mediated diseases. The study consists of a confidential registry where we store your contact, research, and health information, and a sample repository where we keep blood samples for current and future use in our research. The samples will be used for many different studies.

An important part of this study is the sharing of information between researchers of different immune-mediated diseases. The samples and information obtained in this study are part of Benaroya Research Institute’s Immune-Mediated Diseases Registry and Repository.

We may contact you to see if you will come in for additional study visits or to update your health and contact information. We will always tell you what we need and let you decide if you are able to help us at that time. We may also contact you to let you know that you may be eligible for other studies.

Type of participant we are looking for:

• Diagnosed with type 1 diabetes
• Relatives of people with type 1 diabetes
• Live in Seattle area

Clinicaltrials.gov number
None

Who to contact:
Outreach Team at Benaroya Research Institute
Phone number: 1-800-888-4187
Email address: diabetes@BenaroyaResearch.org

Website for more details about the study:
BRIDGE Study of Type 1 Diabetes | Benaroya Research Institute 

This study is testing an investigational drug called frexalimab in adolescents and adults age 12-35 years old with newly diagnosed type 1 diabetes who are on insulin therapy (adults age 18-35 will be enrolled first, followed by 12 to 21-year-olds later in the study).

You will be put into a group by chance (randomized) to receive either the study drug, frexalimab or placebo. The placebo looks just like frexalimab but does not contain any real medicine. It is used to better see if the effect of the study drug (frexalimab) in comparison to no medicine. Your chances of receiving frexalimab is 2 in 3.

You can help researchers understand:

• If frexalimab can preserve the body’s own insulin production.
• If frexalimab can help the body control blood glucose levels.
• If frexalimab can decrease the dose of insulin.
  How safe frexalimab is.

Eligibility Criteria
To be considered for this study you must be:

• Age 12-35 (adults age 18-35 will be enrolled first, followed by 12 to 21-year-olds later in the study)
• Recently diagnosed with type 1 diabetes and taking insulin replacement therapy for 90 days or less.

What will study participants be asked to do?
You will be in the study for about 135 weeks (2.5 years). You will visit the study site about 14 times for tests and health checks. Your study team will also call you between visits to see how you’re doing. Your health will be monitored for any side effects that may happen.

Email: diabetes@benaroyaresearch.org
Phone: 800-888-4187

TrialNet researchers are testing two different treatments – abrocitinib and ritlecitinib – to see if either or both can preserve insulin production in people (ages 12-35) newly diagnosed with type 1 diabetes (Stage 3 T1D).

Abrocitinib and ritlecitinib are in a new class of autoimmune treatments called Janus kinase (JAK) inhibitors. Abrocitinib is approved by the U.S. Food and Drug Administration (FDA) to treat eczema. Ritlecitinib is being studied as a treatment for several autoimmune diseases, including alopecia, ulcerative colitis, Crohn’s disease, vitiligo and rheumatoid arthritis.

Researchers believe abrocitinib and ritlecitinib may be able to calm the immune system response that harms beta cells. Located in the pancreas, beta cells are responsible for making insulin. Continuing to make even a small amount of insulin helps keep blood glucose levels in the normal range, lowering the risk of long-term complications.

As with any medical intervention, there are benefits and risks to participating in this study. Before you join the study, a TrialNet team member will explain all potential benefits and risks and answer your questions.

Eligibility Criteria
You may be eligible to participate if you are:

• Age 12-35
• Newly diagnosed with T1D (in past 3 months)
• Up to date on required vaccines (including the flu vaccine when it is available)
• Not pregnant, breastfeeding or planning to become pregnant while in the study
• AND have:
  • One or more diabetes-related autoantibodies
  • Hemoglobin A1C below 10%
  • C-peptide detectable during a mixed-meal tolerance test (MMTT)

What will study participants be asked to do?
JAKPOT is a two-year study:

• There is a one-year treatment period with daily oral tablets and clinic visits every three months.
• There is a one-year follow-up period with clinic visits every six months.
• All participants will receive guidance for intensive diabetes management and will be expected to wear a Continuous Glucose Monitor (CGM) for 2 weeks after each study visit.

  Email: diabetes@benaroyaresearch.org
  Phone: 800-888-4187

TrialNet is an international network dedicated to the study, prevention and early treatment of type 1 diabetes. TrialNet screens relatives of people with type 1 diabetes for their risk of developing the disease and can identify the early stages of T1D years before symptoms appear.  The study also helps researchers learn more about how T1D develops and plan new studies exploring ways to prevent it.

With a simple blood test TrialNet looks for diabetes-related autoantibodies. If autoantibodies are confirmed to be present, participants will be invited to join the monitoring part of the study and they may be eligible to participate in a prevention trial.

Family members can order test kits to be mailed to them, free of charge, to collect a screening sample at home. To learn more or sign up, visit https://www.TrialNet.org

Type of participant we are looking for:

• Individuals 2 through 45 years old who have an immediate family member with type 1 diabetes (such as a child, parent, or sibling)
• Individuals 2 through 20 years old who have an extended family member with type 1 diabetes (such as a cousin, niece, nephew, aunt, uncle, grandparent, or half-sibling)

Clinicaltrials.gov number
NCT00097292

Who to contact:
Outreach Team at Benaroya Research Institute
Phone number: 1-800-888-4187
Email address: diabetes@BenaroyaResearch.org

Website for more details about the study:
https://www.TrialNet.org

The Rare and Atypical DIAbetes NeTwork (RADIANT) is dedicated to characterizing (discovering and defining) rare and atypical forms of diabetes.

RADIANT is a network of universities, hospitals and clinics across the United States dedicated to better understanding atypical diabetes. Our team of academic institutions and scientists collaborates with physicians and healthcare groups to identify those with atypical diabetes and learn more about their health.

RADIANT is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Type of participant we are looking for:

• Ages 0-80 with an atypical form of diabetes

Website for more details about the study:
https://www.atypicaldiabetesnetwork.org/

DERMIS is an investigational study looking to answer the questions of why pump wearers’ skin changes after a number of years.

Type of participant we are looking for:

• Type 1 adults over the age of 30, who are pump wearers either >20 years or <10 years.

Who to contact:
Dori Khakpour
Email address: dorik@uw.edu

GLIDING: A randomized comparison of transitioning from insulin GLargine to Insulin Degludec usING a bridging dose of glargine versus direct conversion, in patients with type 1 diabetes mellitus, is a small pilot study looking at two regimens (or treatment schedules) for people who switch from taking insulin glargine and insulin degludec.

The main purpose of this study is to see if the participants switching with a bridging dose have less low blood sugars and better blood sugar control vs those who switch with no bridging dose. The results of this research may help design other or larger studies to look at better ways of switching insulins.

Type of participant we are looking for:

• Patient who are type 1 and whose doctor wishes to change their insulin from Glargine to Degludec.

Who to contact:
Thanmai Kaleru
Email address: tkaleru@uw.edu

Researchers at the University of Washington want to learn more about the effects of insulin on diabetic blood. In particular, our study aims to investigate the effects that insulin has on the behaviour of red blood cells in the blood. The information we learn by doing this study may help advance knowledge in the field of diabetes.

What can you expect during this study, if qualified?

• You will be asked to attend a lab on the University of Washington campus for about 1 hour
• Several drops of blood will be extracted from your finger with a lancet, before and after your typical self-injection of insulin
• You will receive $100 for participation

Type of participant we are looking for:

• Are between the ages of 18 and 70
• Have been diagnosed with either Type 1 or Type 2 Diabetes
• Control your diabetes with rapid-acting insulin

Who to contact:
Arazi Pinhas
Phone number: 561-365-7511
Email address: apinhas@cantab.net